semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Traumatic Brain Injury Has sustained a documented TBI that required an inpatient rehabilitation program is at least one year post TBI is at least 18 and no more than 64 years of age at the time of enrollment is English or Spanish speaking is at least three months beyond completion of formal PT, including acute inpatient rehabilitation, outpatient and home-based therapy provides written medical clearance for participation in an in-home balance exercise program ambulates independently within the home (with assistive devices and/or orthotics as needed) has active range of motion of bilateral upper extremities of at least 90 degrees of abduction to allow for control of the VR system completes a 15 minute trial using a VR system in the absence of a negative physical or behavioral reaction self-reports ongoing balance deficits and demonstrate such deficits by scoring at or below one standard deviation above the mean (75 or below) on the CB&M; and  has a history of another medical illness or neurological disorder which may affect balance has experienced a seizure within the last year has a history of psychiatric disorder requiring hospitalization is currently participating in another RCT is currently using VR technology to address specific balance goals is unable to travel to Craig for assessments throughout the study period is unable to communicate effectively to complete standardized assessments has cognitive impairment that precludes completion of baseline testing is unavailable to participate in 12 continuous weeks of therapy has no access to television able to connect to VR-gaming system; and
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Multiple Sclerosis (MS) Relapsing-Remitting MS Primary Progressive MS Secondary Progressive MS Clinically Isolated Syndrome (CIS) Signature of an informed consent Male or female between 18 and 60 years of age Patients with PPMS (Revised McDonald 2010) or patients with SPMS or CIS or patients with RRMS (Revised McDonald 2010) ideally without IFN beta therapy at the T0 visit for RRMS patient only  Positive serology for hepatitis B or C or HIV Acute infection at inclusion Severe psychiatric disorder Autoimmune disease other than MS Pregnancy or breastfeeding Heavy smokers i.e. more than 10 cigarettes per day History of alcohol or drug abuse in the last 3 years Participation in a clinical trial (within the last 3 months)
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Amyotrophic Lateral Sclerosis (ALS) ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial Age 18 years or older Exhibits bulbar dysfunction manifested by dysarthria and/or dysphagia, according to PI judgment, exhibits a score of 55 or above on the CNS-Bulbar Function Scale Capable of providing informed consent and following trial procedures Geographic accessibility to the site Women must not be able to become pregnant for the duration of the study and must be willing to be on two contraceptive therapies Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the screening visit Must be able to swallow capsules throughout the course of the study, according to PI judgment Subjects must not have taken riluzole for at least 30 days or be on a 50mg BID dose of riluzole for at least 30 days prior to randomization (subjects how have never taken riluzole are permitted in the study) Subjects taking anti-sialorrhea medication(s) must be on a stable dose for at least 30 days prior to randomization (anti-sialorrhea naïve subjects are permitted in the study)  Prior use of Nuedexta® Current use of dextromethorphan, quinidine, quinine, mefloquine or opioids History of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions History of known sensitivity or intolerability to dextromethorphan Use of an mono amine oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure Complete atrioventricular (AV) block without implanted pacemaker, or subjects at high risk of complete AV block Concomitant use with drugs that both prolong QT interval and are metabolized by cytochrome P 2D6 (CYP2D6) (i.e., thioridazine or pimozide) Exposure to any other experimental agent (off-label use or investigational) within 30 days prior to Baseline Visit Invasive ventilator dependence, such as tracheostomy
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 20.0-59.0,  Multiple Sclerosis MS Patients Patients who suffer from clinically definite MS with a RR phenotype or CIS Age range from 20-59 years old Not pregnant or nursing Able to understand and sign a consent form No contraindication to MRI and contrast agent Controls Control is a healthy volunteer Aged from 20-59 years old Not pregnant or nursing Able to understand and sign a consent form  MS Patients History of other major illness such as diabetes, chronic renal disease, a prior known neurological disorder other than MS or substances abuse Currently receiving chemo therapy, on dialysis Known contraindication to MRI such as pacemaker, pregnancy, other non-MR compatible implanted device Allergic to MRI contrast Patients with moderate to severe kidney disease that have impaired ability to filter the contrast agents (serum creatinine > 1.8 mg/dL) Younger than 20 or older than 59 Pregnancy or nursing Unable to understand and sign a consent form Controls History of other major illness such as diabetes, chronic renal disease, a prior known neurological disorder or substances abuse Currently receiving chemo therapy, on dialysis
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Relapsing-Remitting Multiple Sclerosis Multiple Sclerosis Key for Part I Must have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) Must have a baseline Expanded Disability Status Scale (EDSS) score between 0.0 and 5.0, inclusive. Key for Part II: • Subjects who participated in and completed Part I per protocol. Key  Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease Pregnant or nursing women. NOTE: Other protocol-defined inclusion/
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Multiple Sclerosis Subject is between 18 and 50 years old Subject has diagnosis of relapsing-remitting MS according to McDonald (2010)  Patient who had hyponatremia in the last 90 days
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infection She is at least 18 years of age She reports having engaged in vaginal or anal sexual intercourse in the past 90 days in exchange for money, alcohol or other goods She reports having engaged in unprotected vaginal or anal sexual intercourse in the past 90 days with a paying sexual partner; and She reports being interested in learning about and developing her own small business  assessed to have a severe cognitive or psychiatric impairment that would interfere with the ability to provide informed consent or complete study instruments
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Multiple Sclerosis Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) or Secondary Progressive MS according to the McDonald 2010 Age 18 to 65 years inclusive Neurostatus (EDSS) score at screening from 0 to 6.5 Fulfill ultrasound for CCSVI  Previous venoplasty and/or stenting of extra cranial venous system
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Relapsing-Remitting Multiple Sclerosis Key Rapidly evolving severe relapsing remitting multiple sclerosis, defined by 2 or more disabling relapses in 1 year, and with 1 or more gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load, as compared to a previous recent magnetic resonance imaging (MRI) Key  History of, or abnormal laboratory values indicative of, significant medical, neurologic (other than MS), or psychiatric disorders that might preclude participation in the study in the opinion of the Investigator Prior natalizumab therapy. NOTE: Other protocol defined Inclusion/
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Relapsing-Remitting Multiple Sclerosis Multiple Sclerosis Key Have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) and satisfy the approved therapeutic indication for DMF (per the local DMF product information) Must be naïve to DMF, Fumaderm®, and other compounded fumarates, and to MS therapies that are primarily prescribed second-line (e.g., natalizumab, fingolimod) and to alemtuzumab Have a recent complete blood count (CBC) that does not preclude the subject's participation in the study, in the judgment of the Investigator. Key  Are unwilling or unable to comply with study requirements, or are deemed unsuitable for study participation as determined by the Investigator Have major comorbid conditions that preclude participation in the study, as determined by the Investigator Are pregnant, unless DMF is clearly needed and the potential benefit of DMF to the subjects justifies the potential risk to the fetus, in the judgment of the Investigator (in all countries except Austria). In Austria, pregnant subjects are excluded from participation in the study Are women of childbearing potential and are not using appropriate contraception (per the local DMF product information) as determined by the Investigator Women who are breastfeeding may be excluded (per the local DMF product information) at the discretion of the Investigator Have previously received or are receiving treatment with MS therapies primarily used second-line (e.g., natalizumab, fingolimod) or alemtuzumab, or are currently receiving and planning to continue on other disease-modifying therapies for RRMS Are hypersensitive to the active ingredient in the DMF drug product (i.e., DMF) or to any of the excipients listed in the local DMF product information Current enrollment in any clinical trial except for the Biogen Idec DMF Pregnancy Exposure Registry or other studies that, according to the study Medical Director, do not conflict with this study (e.g., health economics studies or local registries). Other protocol-defined inclusion/
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Multiple Sclerosis Urinary Bladder Diseases Diagnosis of relapsing-remitting multiple sclerosis and currently being treated by study doctor  Diagnosis of primary-progressive, secondary-progressive, or progressive-relapsing multiple sclerosis
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Stroke individuals aged 40-75 movement-related deficits associated with a middle cerebral artery stroke first time stroke affecting the corona radiata and/or internal capsule Fugl-Meyer upper extremity motor score of at least 15 but not greater than 55  outside the age range of 40-75 show signs of dementia (score < 24 on the Montreal Cognitive Assessment) have aphasia (score < 13 on the Frenchay Aphasia Screen) history of head trauma, a major psychiatric diagnosis, neurodegenerative disorder or substance abuse taking any drugs (GABAergic, N-methyl-D-aspartate A-receptor (NMDA) antagonist) known to influence neuroplasticity report contraindications to MRI (see supporting documents)
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Relapsing-Remitting Multiple Sclerosis Key Must give written informed consent and assent, as applicable Decision to treat with natalizumab must precede enrollment Patient characteristics and contraindications to treatment with natalizumab in accordance with prescribing information Must be receiving natalizumab (Tysabri) for the treatment of RRMS in accordance with the natalizumab indication statement Must have a documented diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS). NOTE: Other protocol defined Inclusion/